HagenbeekA., GadebergO., JohnsonP.. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood.2008; 111(12): 5486–5495.
2.
CoiffierB., LepretreS., PedersenL.M.. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapse or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood.2008; 111(3): 1094–1100.
3.
OsterborgA., KippsT.J., MayerJ.. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial [ASH abstract 328]. Blood.2008; 112. http://ash.confex.com/ash/2008/webprogram/Paper5918.html.
4.
Arzerra [package insert].Research Triangle Park, NC: GlaxoSmithKline; October 2009.
5.
OsterborgA., RonnB.B., JewellR.C.. Correlation between serum ofatumumab concentrations, baseline patient characteristics and clinical outcomes in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) treated with single-agent ofatumumab [ASH abstract 3433]. Blood.2009; 114. http://ash.confex.com/ash/2009/webprogram/Paper23333.html.
6.
PiekarzR.L., FryeR., TurnerM.. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol.2009; 27(32): 5410–5417.
7.
Istodax [package insert].Cambridge, MA: Gloucester Pharmaceuticals Inc; November 2009.
8.
ByrdJ.C., MarcucciG., ParthunM.R.. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood.2005; 105(3): 959–967.
9.
SandorV., BakkeS., RobeyR.W.. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res.2002; 8(3): 718–728.
10.
KlimekV.M., FircanisS., MaslakP.. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res.2008; 14(3): 826–832.
